Solid Dosage Forms

Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Etravirine belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is primarily used in the treatment of HIV-1 infection in combination with other antiretroviral agents. Etravirine works by inhibiting the reverse transcriptase enzyme, thereby reducing viral replication and slowing down the progression of HIV disease.

Etravirine belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is primarily used in the treatment of HIV-1 infection in combination with other antiretroviral agents. Etravirine works by inhibiting the reverse transcriptase enzyme, thereby reducing viral replication and slowing down the progression of HIV disease.

Aminocaproic Acid Tablets USP, 500 mg are essential for managing bleeding disorders associated with increased fibrinolytic activity. Their role in stabilizing clot formation makes them a critical component of treatment in surgical and clotting disorder contexts

Aminocaproic Acid Tablets USP, 1000 mg, are essential for managing bleeding disorders associated with increased fibrinolytic activity. Their role in stabilizing clot formation makes them a critical component of treatment in surgical and clotting disorder contexts

Primidone Tablets USP, available in strengths of 50 mg and 250 mg, are important medications for the management of epilepsy and seizure disorders.

Will be launched by August 7^th, 2024.

Primidone Tablets USP, available in strengths of 50 mg and 250 mg, are important medications for the management of epilepsy and seizure disorders.

Will be launched by August 7^th, 2024.

Primidone Tablets USP, available in strengths of 50 mg and 250 mg, are important medications for the management of epilepsy and seizure disorders.

Will be launched by August 7^th, 2024.

Letrozole Tablets USP, 2.5 mg are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Will be launched soon.